Josh Bilenker, MD, is a proven biopharmaceutical executive who is best known for founding Loxo Oncology and serving as its CEO. Since the acquisition of Loxo Oncology by Eli Lilly and Co. in 2019, Dr. Bilenker.has been working to reorganize the oncology R&D efforts of this multinational pharmaceutical company. Josh Bilenker, MD, entered the pharmaceutical industry following a career as a healthcare venture capital investor at Aisling Capital, from 2006 to 2019.
Dr. Bilenker’s background extends to serving as a fellow within the division of hematology/oncology at the Hospital of the University of Pennsylvania in the early 2000s. As a fellow, he worked in the Phase I unit, cared for patients with breast and GI cancers, and took course work in clinical trial design, statistics and healthcare finance. He went on to work as a medical officer with the Office of Oncology at the U.S. Food and Drug Administration (FDA) for 2 years. His responsibilities focused on regulatory judgments on supplemental biologic licensing applications and investigational new drug applications.
Dr. Bilenker founded Loxo Oncology in 2013, and the company successfully brought innovative drugs to U.S. FDA approval. He helped design clinical trials that gained recognition for efficient enrollment on the basis of tumor genomic profiling, also known as tumor DNA testing. A recognized presence in his field, Josh Bilenker, MD, is active with organizations such as the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the American Society of Hematology (ASH) and Friends of Cancer Research.